Nuravax and others are working on the next wave of Alzheimer’s treatments to catch the disease before symptoms arise.

Lilly dominates GLP-1 market but faces near-term headwinds, while AstraZeneca boasts steady growth, rising estimates and a higher dividend yield.

Helix has released a new suite of pharmacogenomics (PGx) tests, widening its portfolio in neurology and oncology.

The EMA's human medicines committee has said it does not recommend approval of Eli Lilly's anti-amyloid Alzheimer's disease treatment Kisunla, saying its modest benefits don't outweigh its risks.

Eli Lilly says a new starting dose regimen for its Alzheimer's disease therapy Kisunla reduces the risk of side effects that have stood in the way of approvals and reimbursement decisions for ...

The Lumipulse blood test became the first “in vitro diagnostic device” to be endorsed by the U.S. Food and Drug ...

Helix, a leader in precision health, is announcing the release of a new suite of pharmacogenomics (PGx) tests, including a test designed to identify patients with DYPD gene variants who may be at ...

If we haven't been touched by Alzheimer's directly, we know someone who has. In fact, more than 7 million Americans aged 65 ...

On July 2, the U.S. Food and Drug Administration (FDA) granted traditional approval to donanemab (Eli Lilly), sold under the brand name Kisunla, for the treatment of people living with early ...

May 31, 2025 • 'Memory cafes' are small social gatherings for individuals with dementia — and their caregivers, too. As public health funding shrinks, memory cafes are cheap to run and can ...